Mike Oliansky
About Mike Oliansky
Mike Oliansky serves as the Director of Consumer Analytics at GTB, where he has worked since 2004. He has extensive experience in predictive modeling, database research, and statistical methods, with previous roles at Ford Credit, Morpace Inc., and Pfizer.
Work at GTB
Mike Oliansky has served as the Director of Consumer Analytics at GTB since 2004. His role involves initiating and supervising projects aimed at developing predictive models for direct marketing selection. He conducts strategic database research to identify customer migration patterns and marketing opportunities. Additionally, he leads SAS education efforts within the organization, enhancing the analytical capabilities of the team.
Previous Experience
Before joining GTB, Mike Oliansky worked at Ford Credit as a Contract Senior Analyst from 1997 to 2001. In this position, he developed time series analysis techniques to project sales performance against established goals. He also held the role of Research Director at Morpace Inc. from 1994 to 1996, where he contributed to various research initiatives. Prior to these roles, he was a Contract Senior Clinical Programmer/Analyst at Pfizer from 2001 to 2004, where he introduced and evaluated new statistical methods for segmentation.
Education and Expertise
Mike Oliansky holds a Master of Arts in Industrial and Organizational Psychology from Wayne State University. He also earned a Graduate Certificate in Applied Statistics from Oakland University. His educational background provides a strong foundation for his expertise in consumer analytics and statistical methods, which he applies in his current role and previous positions.
Analytical Skills and Contributions
Throughout his career, Mike Oliansky has demonstrated strong analytical skills, particularly in developing predictive models and conducting strategic database research. His work has focused on identifying marketing opportunities and customer migration patterns. He has also contributed to the field of statistics by introducing new methods for segmentation during his tenure at Pfizer.